Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo.
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
read more...
Jan 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
read more...
Jan 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
read more...
